AKT1 and breast carcinoma: Guided by these computational-experimental results, we opened an investigator-initiated tissue-agnostic clinical trial of patients harboring AKT1-3 alterations (ClinicalTrials.gov NCT03310541) that excluded ER+ breast cancer patients harboring AKT1 E17K mutations studied previously (NCT01226316)30.